Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
A phase 3 trial of HPV quadrivalent vaccine in cervical cancer and vulvar cancer, run by Shanghai Bovax Biotechnology Co., Ltd., now recruiting.
Overview
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females is a phase 3 interventional study registered as NCT04422366 by Shanghai Bovax Biotechnology Co., Ltd., with 8000 participants planned, started 2020-04-28 and due to reach its primary completion in 2027-09-15. Interventions recorded: 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL®. Conditions listed: Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialImmunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Shares Vaginal cancer, Cervical cancer.
- JournalJournal of gynecologic oncology
Shares Vulvar cancer, Vaginal cancer, Cervical cancer.
- TreatmentHPV bivalent vaccine (types 16 and 18)
Shares HPV quadrivalent vaccine (types 6, 11, 16 and 18), Cervical cancer.
- TrialStudy of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Shares Vulvar cancer, Cervical cancer.
- TreatmentLorigerlimab
Shares Vulvar cancer, Cervical cancer.
- TreatmentNonavalent HPV vaccine
Shares HPV quadrivalent vaccine (types 6, 11, 16 and 18), Vulvar cancer, Vaginal cancer, Cervical cancer.
- TrialKEYNOTE-826
Shares Vaginal cancer, Cervical cancer.
- JournalInternational journal of gynecological cancer
Shares Vulvar cancer, Vaginal cancer, Cervical cancer.